Comparison of raloxifene and alendronate on markers of cardiovascular health in postmenopausal women with osteoporosis

被引：0
|
作者：
Reginster, JY
Adachi, JR
Qu, Y
Siddhanti, S
Keech, C
机构：
[1] Univ Liegravege, Bone & Cartilage Metab Unit, Liegravege, Belgium
[2] Univ Liegravege, Dept Epidemiol & Publ Hlth, Liegravege, Belgium
[3] McMaster Univ, Dept Med, St Josephs Hosp, Hamilton, ON, Canada
[4] Lilly Res Labs, Indianapolis, IN USA
来源：
OSTEOPOROSIS INTERNATIONAL | 2003年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S42 / S42
页数：1
相关论文
共 50 条
  • [41] Alendronate in postmenopausal osteoporosis
    Liedholm, H
    Linne, AB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (11): : 733 - 734
  • [42] Comparison of the effect of raloxifene on bone between Japanese and Caucasian postmenopausal women with osteoporosis.
    Nakamura, T
    Matsumoto, T
    Fukunaga, M
    Watts, S
    Harper, KD
    Uesaka, H
    Tsujimoto, M
    Hamaya, E
    Sato, K
    Tanaka, A
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S301 - S301
  • [43] A 12 months comparative study of raloxifene and alendronate treatment in postmenopausal women
    Gulerman, CH
    Turkcapar, F
    Dabakoglu, T
    Tongue, E
    Mollamahmutoglu, L
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (06): : 799 - 799
  • [44] Ten years of alendronate treatment for osteoporosis in postmenopausal women
    Chan, AS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (02): : 190 - 190
  • [45] Effect of alendronate on bone density and bone markers in postmenopausal osteoporosis
    Aki, S
    Gulbaba, RG
    Eskiyurt, N
    [J]. JOURNAL OF BACK AND MUSCULOSKELETAL REHABILITATION, 2003, 17 (01) : 27 - 31
  • [46] DIFFERENCES IN EARLY DYNAMICS OF SERUM BONE MARKERS IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS TREATED BY ALENDRONATE OR RISEDRONATE
    Sferrazza, C.
    Carmina, E.
    Cannone, V.
    Avila, D.
    Sutera, L.
    Rini, G. B.
    Di Fede, G.
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2004, 74 : S97 - S97
  • [47] Differences in early dynamics of serum bone markers in women with postmenopausal osteoporosis treated by alendronate or risedronate
    Sferrazza, C
    Napoli, N
    Cannone, V
    Cusumano, G
    Rini, G
    Di Fede, G
    [J]. BONE, 2005, 36 : S422 - S423
  • [48] Comparison of alendronate and raloxifene to prevent bone loss when estrogen therapy is discontinued in postmenopausal women.
    McClung, MR
    Omizo, M
    Mossman, E
    Conn, D
    Workman, P
    Chen, E
    de Papp, AE
    Kocher, M
    Watts, N
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S397 - S397
  • [49] Cost effectiveness of pharmaceutical interventions in postmenopausal women: A comparison of raloxifene, hormone replacement therapy, and alendronate.
    Tosteson, ANA
    Van Orden, LS
    Minshall, ME
    Grove, M
    Moncur, M
    Kneeland, TS
    Muchmore, DB
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S398 - S398
  • [50] Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene
    Cosman, Felicia
    Keaveny, Tony M.
    Kopperdahl, David
    Wermers, Robert A.
    Wan, Xiaohai
    Krohn, Kelly D.
    Krege, John H.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28 (06) : 1328 - 1336
12345